Detection of pseudoprogression using CT perfusion in patients with Glioblastoma Multiforme post-treatment

Detection of pseudoprogression using CT perfusion in patients with Glioblastoma Multiforme post-treatment: an observational cohort study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN68166254

Enrollment

Registered

2015-07-01

Start date

2015-05-01

Completion date

Unknown

Last updated

2018-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma Multiforme Cancer

Interventions

A single CT perfusion scan will be carried out during the study. The study will be prospective and each patient will follow the procedure below: Newly diagnosed patients with glioblastoma multiforme t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with glioblastoma multiforme tumours who will be discussed in the regional neuro-oncology multidisciplinary team meeting 2. Patients exhibiting any tumour progression on their first follow-up imaging immediately after radiotherapy, surgery or chemotherapy post-treatment without clinical progression

Exclusion criteria

Exclusion criteria: Patients who exhibit tumour progression both clinically (symptoms) and on imaging on the first follow-up imaging immediately following radiotherapy, chemotherapy or surgery following treatment

Design outcomes

Primary

Measure	Time frame
Diagnosis of true tumour progression measured by MRI scan 8 weeks after treatment	—

Secondary

Measure	Time frame
Better diagnosis and improved treatment options	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026